Jeremie Calais, MD, MSc, presented “PSMA PET Imaging in Advanced Prostate Cancer” virtually during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 15th, 2020.
How to cite: Calais, Jeremie. “PSMA PET Imaging in Advanced Prostate Cancer” October 15th, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/psma-pet-imaging-in-advanced-prostate-cancer/
Summary:
Jeremie Calais, MD, MSc, Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division at UCLA, discusses the use of prostate-specific membrane antigen PET imaging, or PSMA PET, in diagnosing advanced prostate cancer. Noting that PSMA PET is currently the most sensitive imaging technique, he reviews well-known studies, STOMP and ORIOLE, and shares patient success stories of PSMA PET guided therapy. PSMA PET is able to detect tumor deposits of 4.5 mm with 90% accuracy and 2.3 mm with 50% accuracy making it more effective in locating disease migration. However, there will still be some micrometastases that are too small to yet be detected by PSMA PET. Because active distant lesions are not successfully identified under all imaging types, Dr. Calais proposes including the modality employed when stating a patient’s disease progression; for example, “mCRPC by PSMA-PET,” thereby expressing the means by which the disease stage was determined. PSMA PET can be used to follow disease mutation and more quickly identify non-metastatic castration-resistant prostate cancer.
For more on recent advances in this topic, please see this interview with Robert E. Reiter, MD, on the recent FDA approval of PSMA PET for prostate cancer.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics.
ABOUT THE AUTHOR
Dr. Jeremie Calais received his MD from the University of Paris-Diderot in 2010 before training in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center at the University of Rouen. He was board certified by the French Society of Nuclear Medicine in 2014. Dr. Calais is Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA, where he is also a member of the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology. Under Dr. Calais’s guidance, the clinical research program focuses on translatable radiolabeled theranostic pairs that can be used and applied for diagnosis and therapy of cancer and combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. Dr. Calais’s work focuses on improving the outcomes of cancer patients by applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning, and therapy response assessment and currently serves as Principal Investigator of randomized prospective phase 2 and 3 clinical trials.
